EUVIMEDEUVIMED entdecken
Crossref

Niosomes for enhanced oral delivery of pioglitazone: in vitro characterization and in vivo evaluation

Aya R Elbasuony iD, Abdelaziz E Abdelaziz, Eman A Mazyed, Gamal M El Maghraby

Journal of Pharmacy and Pharmacology · 2025

DOI: 10.1093/jpp/rgaf015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Aya R Elbasuony und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Thiazolidinediones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim was to investigate oleic acid and nigella oil modified niosomes as novel carriers for enhanced pioglitazone (PGZ) oral delivery.

Methods

PGZ was encapsulated into niosomes of cholesterol, tween 80, and span 60 before (F1) and after incorporation of nigella oil (F2) or oleic acid (F3) as membrane fluidizers. Niosomes were characterized for morphology, size, zeta potential, PGZ entrapment, and release. Hypoglycemic effect was also assessed. Key findings Vesicles were spherical recording size values of 286.4, 111.3, and 137.5 nm for F1, F2, and F3 niosomes, respectively. The zeta potential predicted good stability of niosomes. The lipophilic nature of PGZ resulted in more than 99% entrapment into niosomes. PGZ niosomes significantly boosted rate and extent of hypoglycemic activity compared with the unprocessed PGZ. This is clear from the Tmax, which was 3.6, 1.5, 0.87, and 0.62 h for control, F1, F2, and F3, respectively. This was associated with increase in the area above hypoglycemia curve, which was 655.8, 1613.6, 1617.2, and 1764.9 mg h/dl for the same formulations, respectively.

Conclusion

Vesicular structure is responsible for enhanced oral bioavailability and drug release is not the limiting factor. Fluidizing material showed potential contribution in enhanced efficacy but requires future verification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoglycemic AgentsThiazolidinedionesPioglitazoneLiposomesAdministration, OralAnimalsMaleDrug LiberationPolysorbatesOleic AcidRatsParticle SizeCholesterolDrug CarriersBlood GlucoseDrug Delivery SystemsHexosesBiological Availability

Stichwörter der Autor:innen

in vivodrug releaseniosomesoral bioavailabilitypioglitazone

Substanzen

PioglitazoneLiposomesHypoglycemic AgentsPolysorbatesOleic AcidThiazolidinedionesCholesterolDrug CarriersBlood GlucoseHexoses

Autor:innen und Institutionen

  • Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
  • Faculty of Pharmacy, Tanta University, Tanta, Egypt.

ORCID-Profile: Aya R Elbasuony

Zitieren

APA

Elbasuony, A. R., Abdelaziz, A. E., Mazyed, E. A., & El Maghraby, G. M. (2025). Niosomes for enhanced oral delivery of pioglitazone: in vitro characterization and in vivo evaluation. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf015

Vancouver

Elbasuony AR, Abdelaziz AE, Mazyed EA, El Maghraby GM. Niosomes for enhanced oral delivery of pioglitazone: in vitro characterization and in vivo evaluation. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf015

BibTeX
@article{Elbasuony2025,
  author = {Elbasuony, Aya R and Abdelaziz, Abdelaziz E and Mazyed, Eman A and El Maghraby, Gamal M},
  title = {Niosomes for enhanced oral delivery of pioglitazone: in vitro characterization and in vivo evaluation},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2025},
  doi = {10.1093/jpp/rgaf015}
}
Kostenlos starten →